Adcendo Announces US FDA Clearance of IND Application for Phase I/ II First-in-Human ADCElerate-01 Trial of ADCE-D01 Trial in Patients With Metastatic and/ or Unresectable Soft Tissue Sarcoma

Adcendo United Kingdom

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple STS subtypesThe Phase I/II ADCElerate-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STSView original content:https://www.prnewswire.co.uk/news-releases/adcendo-announces-us-fda-clearance-of-ind-application-for-phase-iii-first-in-human-adcelerate-01-trial-of-adce-d01-uparap-receptor-targeting-adc-trial-in-patients-with-metastatic-andor-unresectable-soft-tissue-sarcoma-sts-302268931.html